Recent developments in the health sector include Indian pharmaceutical stocks' dip due to tariff threats, mass FDA layoffs ...

Bagsværd: Novo Nordisk HA has announced that Camilla Sylvest has decided to leave the company after a distinguished career of ...

Camilla Sylvest has moved on from Novo Nordisk after 28 years with the Danish pharma, including more than seven years as EVP ...

This brief covers significant developments in health, including FTC's hold on an insulin lawsuit, Hungary's outbreak control ...

Effective 3 April 2025, Novo Nordisk will undergo key changes in its Executive Management. Camilla Sylvest, a long-time leader with 28 years at t ...

Novo Nordisk's head of commercial strategy and corporate affairs, Camilla Sylvest, has decided to leave the company, the ...

European stock markets plunged in Thursday trading following sweeping trade tariffs levied by the US, with the Stoxx Europe 600 dropping 2.57%, Germany's DAX falling 3.01%, the FTSE 100 in London ...

Novo Nordisk is shaking up its executive team as it bids adieu to its longtime head of commercial strategy and corporate ...

Novo Nordisk has announced major leadership changes, with EVP Camilla Sylvest departing and Ludovic Helfgott taking on an ...

Bernstein analyst Florent Cespedes maintained a Hold rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK620.00.

Novo Nordisk (NVO) executive Camilla Sylvest is departing the drugmaker after 28 years, Bloomberg’s Sara Sjolin reports. Sylvest has served as ...

Novo Nordisk (NVO) said Thursday Camilla Sylvest has decided to leave the company, after a distinguished career of 28 years ...